Address
Email address
Phone number
https://genecode.comGenecode - Developing novel
disease modifying drugsOur mission is a simple question we ask ourselves — can we slow down or stop neurodegeneration when treating chronic neurological diseases?
Name
GeneCode AS
Registry code
10362550
VAT number
EE101059031
Type
AS - Joint Stock Company
Status
Registered
Foundation date
15.01.1998 (26)
Financial year
01.01-31.12
Capital
75 600.00 €
Activity
72111 - Research and experimental development on biotechnology
-
951 155 €
-
2 797 €
(estimate is approximate)
4 814 959 €
3
Submitted
No tax arrears
20%
16%
| Owner | Representative | Beneficial owner | Roles | |
|---|---|---|---|---|
| AnsonBaer Nordic OÜ 11365489 | 40% - 30 240.00 EUR | - | - | Shareholder |
| MPPS Investeeringud OÜ 10634869 | 25% - 18 900.00 EUR | - | - | Shareholder |
| Paavo Pilv 12.02.1976 (48) | - | Board member | - | |
| Mart Saarma 29.06.1949 (75) | - | - | Member of a higher management body, i.e. board member or supervisory board member | Board member |
| Thomas Björn Waldin 01.08.1942 (82) | - | - | Direct ownership | Board member |
| Hendrik Hindov 22.08.1976 (48) | - | - | - | Board member |
| Mehis Pilv 13.01.1947 (77) | - | - | - | Board member |
| Owner | Representative | Beneficial owner | Roles | |
|---|---|---|---|---|
| CERE Code AS 11553038 | - | - | - | Founder |
| OliCode AS 11386741 | - | - | - | Founder |
| NeuronCode AS 11386497 | - | - | - | Founder |
| 2019 10.11.2020 | 2020 03.09.2021 | 2021 06.06.2022 | 2022 20.06.2023 | 2023 05.04.2024 | |
|---|---|---|---|---|---|
| Total Revenue | - | 4 250 € | 0 € | - | - |
| Net profit (loss) for the period | -28 481 € | -26 692 € | -69 880 € | 1 262 642 € | 951 155 € |
| Profit Margin | - | -628% | - | - | - |
| Current Assets | 5 502 € | 4 851 € | 20 240 € | 509 297 € | 848 038 € |
| Fixed Assets | 2 672 921 € | 2 685 528 € | 2 626 763 € | 3 789 940 € | 5 171 290 € |
| Total Assets | 2 678 423 € | 2 690 379 € | 2 647 003 € | 4 299 237 € | 6 019 328 € |
| Current Liabilities | 31 892 € | 2 797 € | 45 840 € | 228 926 € | 945 857 € |
| Non Current Liabilities | 1 041 236 € | 1 108 979 € | 0 € | 206 506 € | 258 512 € |
| Total Liabilities | 1 073 128 € | 1 111 776 € | - | 435 432 € | 1 204 369 € |
| Share Capital | 37 800 € | 37 800 € | 75 600 € | 75 600 € | 75 600 € |
| Equity | 1 605 295 € | 1 578 603 € | 2 601 163 € | 3 863 805 € | 4 814 959 € |
| Employees | 0 | 0 | 0 | 3 | 3 |
| Turnover | State taxes | Labor taxes and payments | Employees | |
|---|---|---|---|---|
| 2024 Q1 | 77 554.45 € | - | 10 422.38 € | 2 |
| 2023 Q4 | 20 549.53 € | 8 807.33 € | 11 947.89 € | 3 |
| 2023 Q3 | 188 978.21 € | 9 883.78 € | 12 072.96 € | 3 |
| 2023 Q2 | 266 351.85 € | 8 723.06 € | 11 947.89 € | 3 |
| 2023 Q1 | 376 039.19 € | 10 694.12 € | 11 842.01 € | 3 |
| 2022 Q4 | 267 047.88 € | - | 10 880.91 € | 3 |
| 2022 Q3 | 314 082.38 € | 9 152.94 € | 12 302.05 € | 3 |
| 2022 Q2 | 636 876.6 € | - | 5 847.23 € | 3 |
| 2022 Q1 | 4 604.15 € | 1 663.32 € | 5 461.82 € | 3 |
| 2021 Q4 | 3 162.83 € | - | - | - |
| 2021 Q3 | - | - | - | - |
| 2021 Q2 | 4 910 € | - | - | - |
| 2021 Q1 | 6 636.19 € | - | - | - |
| 2020 Q4 | 12 606.41 € | - | - | - |
| 2020 Q3 | - | - | - | - |
| 2020 Q2 | 4 250 € | 817.06 € | - | - |
| 2020 Q1 | 1 396.57 € | - | - | - |
